List view / Grid view
14 August 2018 | By European Pharmaceutical Review
Current advice points to single or occasional use of the drug, and it is not recommended to be used for longer than four weeks...
9 August 2018 | By European Pharmaceutical Review
Doxorubicin induced irreversible dysregulation which decreased the levels of lipoxygenases and cyclooxygenases in the left ventricle...
6 August 2018 | By European Pharmaceutical Review
Some drugs with active ingredient valsartan have been recalled due to presence of impurity NMDA...
31 July 2018 | By European Pharmaceutical Review
Researchers are now looking to identify if BACE1 is involved in adult hippocampal neurogenesis, and responsible for the brains ability to repair itself...
25 July 2018 | By Mike Stones
Boosting the safety of compounded drugs is the aim of new plan from the US Food and Drug Administration (FDA), which has unveiled a series of measures.
24 July 2018 | By Mike Stones
The pharmacovigilance of new drugs and drug formulations undertaken in New Zealand should be proactive, says a leading expert.
20 July 2018 | By European Pharmaceutical Review
A drug currently in trials for Parkinson's disease has shown promise in treating heart failure, without the risk of dangerous side effects...
13 July 2018 | By European Pharmaceutical Review
Results of a study suggest the need for caution in the prescription of direct oral anticoagulants for patients with chronic kidney disease, due to the risk of bleeding...
5 July 2018 | By European Pharmaceutical Review
Direct oral anticoagulants (DOACs) used to treat serious blood clots are associated with reduced risks of major bleeding compared with the older anti-clotting drug, warfarin, finds a new study.
2 July 2018 | By European Pharmaceutical Review
Higher daily doses of rifampin, a cornerstone of tuberculosis treatment, were shown to kill more TB bacteria in sputum cultures without increasing the adverse effects of treatment, according to a recent randomised controlled trial.
31 May 2018 | By DSM
Both over-the-counter (OTC) and prescription medications are used every day to manage many health problems...
24 May 2018 | By European Pharmaceutical Review
Percutaneous coronary intervention (PCI), along with prescribed medication, is better than medication alone as initial treatment for people with the most common form of heart disease.
21 May 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Pregnant mothers may use rheumatoid arthritis drugs without increased health risks to unborn baby...
10 May 2018 | By European Pharmaceutical Review
The U.S. Food and Drug Administration has approved Tafinlar and Mekinist administered together, for the treatment of anaplastic thyroid cancer that cannot be removed by surgery...
10 May 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Scientists have identified a mutation that gives cancer cells resistance to the breakthrough cancer treatment olaparib and other PARP inhibitors...
Send this to a friend
Follow: